ESPERITE (Euronext ESP) pioneers first treatment worldwide of Cerebral Palsy using two types of stem cells

CryoSave, part of ESPERITE, is the only private cord blood bank sponsoring a GCPclinical trial according to GMP-ATMP international guidelines

CryoSave leads and sponsors a multicentre clinical trial following GCP-ICHstandards, for investigation of new treatment of Cerebral Palsy using dual infusionof two types of stem cells derived from umbilical cord blood and cord tissueprocessed by CryoSave

Geneva, Switzerland - 23 February 2015

The clinical trial aims to demonstrate safety and preliminary efficacy of sequential intravenousinfusion of the ex vivo expanded mesenchymal stem cells (MSC) derived from cord tissue and thecord blood stem cells. The study will use, for the first time in clinical research, autologous MSC

derived from cryopreserved cord tissue. The clinical trial, sponsored by CryoSave, will be performedin collaboration with Professor Manuel Ramrez Orellana, the Principal Investigator, and ProfessorLuis Madero, the Clinical Supervisor from the University Hospital Nio Jesus in Madrid, Spain.

Cerebral Palsy is a devastating disease diagnosed in 1 per 326 children according to CDC, with noavailable treatment. 17 Million people worldwide live affected by cerebral Palsy (CPIRF). 26 BillionUSD are spent every year to accommodate the life of these patients in the US (WHO).

Original post:
ESPERITE (Euronext ESP) pioneers first treatment worldwide of Cerebral Palsy using two types of stem cells